Ten drugs to help treat coronavirus

Independent scientific experts, having studied 82 drugs for the possible treatment of coronavirus, have identified the ten most promising and effective.

Slate.fr (translated by InoPressa) writes:

(…) “A panel of independent scientific experts reviewed 82 candidate drug candidates that had reached advanced clinical development. They then selected the 10 most promising to create a European portfolio of treatments against Covid-19, taking into account the need different types of products depending on patient groups and the stage and severity of the disease. This list of 10 drugs, divided into three categories, will continue to evolve as more scientific evidence emerges. “

1. Scientists emphasize that antiviral drugs should be prescribed to patients as early as possible after confirmation of coronavirus infection. They work inside the virus to prevent it from replicating (the process of creating two daughter DNA molecules from the parent). On the list of antiviral drugs:

molnupiravir from Ridgeback Biotherapeutics and MSD; paxloid (or PF-07321332) from Pfizer; AT-527 from Atea Pharmaceuticals and Roche.

These medicines must be affordable so that they can be quickly taken by those most at risk of severe illness and for whom the benefit / risk ratio is favorable.

2. Monoclonal antibodies to the spike protein, which stimulate an adequate immune response, should also be used at an early stage of the disease, after the first symptoms appear. These drugs are of great interest for use in the event that vaccines partially lose their effectiveness against a new strain. It:

Ronaprev, a combination of two monoclonal antibodies (casirivimab and imdevimab) from Regeneron Pharmaceuticals and Roche; Xevudi (sotrovimab) from Vir Biotechnology and GlaxoSmithKline; evusheld, a combination of two monoclonal antibodies (thixagevimab and cilgavimab) from AstraZeneca.

3. Immunomodulators, anti-inflammatory drugs, are designed to combat serious damage to the coronavirus, to prevent the consequences of a cytokine storm (the body’s reaction in which the level of cytokines in the blood increases sharply, which leads to an attack of immunity on the cells and tissues of its own body). It:

actemra (tocilizumab) from Roche Holding; kinneret (anakinra) from Swedish Orphan Biovitrum; olumiant (baricitinib) from Eli Lilly; lenzimulab from Humaningen.

The authors of the publication emphasize:

(…) “Thus, these first drugs can be approved in the near future in the countries of the European Union, if the final data confirm their quality, and if their balance between benefits and risks turns out to be favorable.”





Source link

High-quality journalistic work cannot be free, otherwise it becomes dependent on the authorities or the oligarchs.
Our site is solely funded by advertising money.
Please disable your ad blocker to continue reading the news.
Best regards, editors